Literature DB >> 17954122

Choice of surgical lesion set: answers from the data.

A Marc Gillinov1.   

Abstract

Surgical ablation of atrial fibrillation has gained widespread acceptance, particularly in patients having concomitant cardiac surgery. Today, surgeons can choose from a variety of ablation technologies to facilitate operations intended to treat atrial fibrillation. Evidence suggests that virtually all of the available energy sources are effective at creating lines of conduction block on the arrested heart. However, there is controversy surrounding the choice of lesion set when these new devices are used. The purpose of this review is to address the critical question of lesion set by detailed consideration of contemporary data focusing on the (1) pathogenesis of atrial fibrillation, (2) results of catheter ablation, and (3) results of surgical ablation.

Entities:  

Mesh:

Year:  2007        PMID: 17954122     DOI: 10.1016/j.athoracsur.2007.05.040

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Left atrial ablation for atrial fibrillation: creating the "box lesion" with a bipolar radiofrequency device.

Authors:  Leonid Sternik; Hartzel V Schaff; David Luria; Michael Glikson; Alexander Kogan; Ateret Malachy; Maya First; Ehud Raanani
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Prophylactic arrhythmia surgery in association with congenital heart disease.

Authors:  Constantine Mavroudis; Barbara J Deal
Journal:  Transl Pediatr       Date:  2016-07

Review 3.  Surgery for Atrial Fibrillation: Selecting the Procedure for the Patient.

Authors:  Rui Providência; Sérgio Barra; Carlos Pinto; Luís Paiva; José Nascimento
Journal:  J Atr Fibrillation       Date:  2013-06-30

4.  Probability of atrial fibrillation after ablation: Using a parametric nonlinear temporal decomposition mixed effects model.

Authors:  Jeevanantham Rajeswaran; Eugene H Blackstone; John Ehrlinger; Liang Li; Hemant Ishwaran; Michael K Parides
Journal:  Stat Methods Med Res       Date:  2016-01-05       Impact factor: 3.021

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.